092123_OML_CME_MM_CME_Info

Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC.

ACKNOWLEDGEMENT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

DATE OF RELEASE/EXPIRATION

This activity was released on September 21st, 2023 and is valid until September 21st, 2024. Requests for credit must be made no later than September 21, 2024.

TARGET AUDIENCE

The educational design of this activity addresses the needs of – Hematologic oncologists, hematologists, medical oncologists, pathologists, and specialty advanced practice providers (NPs and PAs)

STATEMENT OF NEED/PROGRAM OVERVIEW

Decades of progress and several landmark advancements have led to today’s standard-of-care frontline therapies for multiple myeloma (MM), which consist of immunomodulatory agents, proteasome inhibitors, and anti-CD38 antibodies. However, efficacy is not durable, with the majority of patients eventually relapsing due to induced drug resistance or emergence of genetically heterogeneous subclones.

To explore both current and emerging treatment options for MM, join a panel of expert hematologists and oncologists to discuss new clinical data on treatments, their differences and mechanisms of action, and how to anticipate and manage side effects. Panelists will also explore patient and caregiver preferences, the shared decision-making process, and strategies to resolve disparities in treatment priorities.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Describe the rationale behind the development of new therapies for RRMM
• Evaluate clinical data related to new MOAs, such as bispecific antibodies in development for RRMM
• Discuss the role of patient and caregiver preferences in the shared decision-making process and how to align treatment priorities

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For additional information about the accreditation of this activity, please visit https://partnersed.com.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.